Crescent Biopharma (CBIO) Amortization of Deferred Charges (2019 - 2021)
Crescent Biopharma (CBIO) reported Amortization of Deferred Charges of $189440.0 for Q3 2021, up 10.08% year-over-year from $172091.0 in Q3 2020, and up 2.44% quarter-over-quarter from $184935.0 in Q2 2021.
Crescent Biopharma (CBIO) Amortization of Deferred Charges (2019 - 2021) Analysis & Trends
Crescent Biopharma (CBIO) has 3 years of Amortization of Deferred Charges data on file, last reported at $189440.0 in Q3 2021.
- Amortization of Deferred Charges for Q3 2021 came in at $189440.0, up 10.08% year-over-year; the trailing twelve-month figure through Sep 2021 was $731302.0 (up 9.97% YoY), and the FY2020 annual result was $680845.0, up 9.8% from the prior year.
- Amortization of Deferred Charges grew to $189440.0 in Q3 2021 per CBIO's latest filing, from $184935.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $189440.0 in Q3 2021 and troughed at $149686.0 in Q1 2019.
- A 3-year average of $168715.8 and a median of $168151.0 in 2020 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2020 and 2021: Amortization of Deferred Charges gained 9.74% in 2020, then increased 10.08% in 2021.
- A 3-year view of Amortization of Deferred Charges shows it stood at $160469.0 in 2019, then grew by 9.89% to $176341.0 in 2020, then rose by 7.43% to $189440.0 in 2021.
- Business Quant data shows CBIO's Amortization of Deferred Charges at $189440.0 in Q3 2021, $184935.0 in Q2 2021, and $180586.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Crescent Biopharma | 486.92 Mn | 297.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 189,440.00 |
| Sep 30, 2021 | 189,440.00 |
| Jun 30, 2021 | 184,935.00 |
| Jun 30, 2021 | 184,935.00 |
| Mar 31, 2021 | 180,586.00 |
| Mar 31, 2021 | 180,586.00 |
| Dec 31, 2020 | 176,341.00 |
| Dec 31, 2020 | 176,341.00 |
| Sep 30, 2020 | 172,091.00 |
| Sep 30, 2020 | 172,091.00 |
| Jun 30, 2020 | 168,151.00 |
| Jun 30, 2020 | 168,151.00 |
| Mar 31, 2020 | 164,262.00 |
| Mar 31, 2020 | 164,262.00 |
| Dec 31, 2019 | 160,469.00 |
| Dec 31, 2019 | 160,469.00 |
| Sep 30, 2019 | 156,756.00 |
| Sep 30, 2019 | 156,756.00 |
| Jun 30, 2019 | 153,157.00 |
| Jun 30, 2019 | 153,157.00 |